Search results
Showing 7876 to 7890 of 8314 results
Agenda and papers of the NICE public board meeting on 17 March 2022
We're working with colleagues to ensure that virtual wards are used in a way that maximises the value for patients and the NHS.
A step-by-step timeline of the process we used to develop single technology appraisals (STA).
Read NICE's statement on modern slavery and human trafficking.
Ask an expert from NICE International, part of the UK's National Institute for Health and Care Excellence, to speak at a healthcare event in your country
Get expert advice and support from NICE International, part of the UK's National Institute for Health and Care Excellence, for a project in your country
Tools for building or evaluating a medtech evidence base with NICE
Our indicators measure outcomes that reflect the quality of care or processes linked by evidence to improved outcomes.
The Office for Digital Health strives to accelerate NICE's efforts to deliver innovation to the health and care system.
Home Implementing NICE guidance Social care...
Home About us...
Information about NICE's gender pay gap data for the 12 months leading up to 31 March 2025.
NICE's technology appraisal guidance makes recommendations on the use of new and existing medicines and other treatments within the NHS.
The benefits from donanemab (also called Kisunla and made by Eli Lilly) and lecanemab (also called Leqembi and made by Eisai) - remain too small to justify the additional cost to the NHS, one of our independent committees has concluded following consultation.
Some people with cystic fibrosis are set to benefit from a new once-daily triple therapy treatment, following NICE's recommendation of Alyftrek in final draft guidance published today.